Semorinemab Fails to Show Efficacy in Early Alzheimer’s Phase 2 Trial
Note: This story was updated Oct. 12, 2020, to note that semorinemab is intended to target phosphorylated and non-phosphorylated forms of tau. Semorinemab, a monoclonal antibody against tau, failed to significantly alter dementia’s progression in people with early Alzheimer’s disease (AD) taking part in a Phase 2 clinical…